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Abstract
Background and objective
The Brahma gene (BRM) encodes a catalytic ATPase subunit of the Switch/Sucrose non-
fermentable (SWI/SNF) complex, which modulates gene expression and many important
cellular processes. Two indel polymorphisms in the promoter region of BRM (BRM-741 and
BRM-1321) are associated with its reduced expression and the risk of susceptibility or sur-
vival outcomes in multiple solid cancers. In this study, we have examined these variants in
relation to susceptibility and survival outcomes in colorectal cancer.
Methods
Genotypes were obtained using TaqMan assays in 427 cases and 408 controls. Multivariate
logistic and Cox regression models were fitted to examine the associations of the BRM-741
and BRM-1321 genotypes adjusting for relevant covariates. Sub-group analyses based on
tumor location and patient sex were also performed. In all analyses, indels were examined
individually as well as in combination.
Results
Our results showed that there was no association between the BRM polymorphisms and the
risk of colorectal cancer. However, genotype combinations of the BRM-741 and BRM-1321
variants were associated with the risk of colon cancer. Particularly, patients having at least
one variant allele had increased risk of colon cancer when compared to patients with the
double wild-type genotype. In the survival analyses, BRM-741 heterozygosity was associ-
ated with longer progression-free survival time in the colorectal cancer patients. A stronger
association was detected in the male patients under the recessive genetic model where the
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homozygosity for the variant allele of BRM-741 was associated with shorter progression-
free survival time.
Conclusions
Our analyses suggest that BRM-741 and BRM-1321 indels are associated with the risk of
developing colon cancer and the BRM-741 indel is associated with the disease progression
in colorectal cancer patients, especially in the male patients. Although our results show a dif-
ferent relationship between these indels and colorectal cancer compared to other cancer
sites, they also suggest that BRM and its promoter variants may have biological roles in sus-
ceptibility and survival outcomes in colorectal cancers. Performing further analyses in addi-
tional and larger cohorts are needed to confirm our conclusions.
Introduction
Each year, around 1.4 million people are diagnosed with colorectal cancer and about 700,000
deaths occur because of it [1]. In Canada, around one in 15 people are expected to be diag-
nosed with this disease in their lifetime [2]. Worldwide, ~40–66% colorectal cancer patients do
not survive 5-years after diagnosis [3]. Understanding factors, including genetic factors, that
influence the susceptibility to this disease and patient prognosis can help improve its control
and patient survival outcomes. For this reason, many studies have examined the associations
of genetic variations with the risk of developing colorectal cancer or clinically important events
after diagnosis [4–11].
BRM encodes Brahma, one of the two mutually exclusive DNA-dependent ATPase subunits
of the SWI/SNF complex [12]. The SWI/SNF complex includes several subunits, exists in mul-
tiple forms with different subunit compositions, facilitates transcriptional regulation through
remodeling of the chromatin, and is known to play critical roles in many important biological
processes, such as cell proliferation and differentiation [13, 14]. Not surprisingly, several alter-
ations of the multiple SWI/SNF complex subunits (including of BRM) have been identified in
cancer, linking them to carcinogenesis or disease progression [14, 15].
Loss of BRM is often observed in various types of tumors [16–20], which is mainly medi-
ated through epigenetic silencing [16]. Two promoter polymorphisms, BRM-741 and BRM-
1321, are highly correlated with the expression levels of BRM [21]. Both of these polymor-
phisms are indel/repeating sequence variants [21]. BRM-741 consists of two (deletion or wild-
type allele = Del) or three (insertion or variant allele = Ins) copies of a 7 bp long sequence
(TATTTTT) located 741 bp upstream of the BRM transcription start site. BRM-1321, on the
other hand, exists as either one (deletion or wild-type allele = Del) or two copies (insertion or
variant allele = Ins) of a 6 bp long sequence (TTTTAA) located further upstream of the BRM
transcription start site [21]. Variant sequences of these two polymorphisms are highly homolo-
gous to the binding site for myocyte enhancer factor-2 (MEF-2), which together with histone
deacetylases (HDACs) has been shown to epigenetically silence the BRM gene [21, 22]. In
examination of tissue samples, Liu et al. [21] associated the homozygosity for the variant allele
(Ins/Ins) in either or both of the indels with the absence of BRM protein in both lung tumor
and unaffected tissues. Examination by Gao et al. [23] showed that in both hepatocellular car-
cinoma tumors and non-tumor tissues the BRM expression levels decreased similarly with
each Ins allele of BRM-1321. It is not known at the time being whether the Ins allele of BRM-
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741 has a similar effect on BRM expression as in the case of BRM-1321 (i.e. expression levels
decreasing similarly with each copy of the Ins allele), but considering the fact that the BRM
silencing is mediated through the binding of the MEF-2 and HDACs to the Ins alleles [21,22],
it is a plausible possibility. Last but not least, both indels are linked to each other to varying
degrees in different populations (D’ = 0.39–0.86) [20, 21, 23–26] and are common in Cauca-
sians with similar minor allele frequencies (MAFs) of 45% [21].
Because BRM-741 and BRM-1321 can affect the expression of BRM and thus the activity of
SWI/SNF, it is reasonable to suspect that these two polymorphisms may influence the risk or
prognosis of human cancers. Supporting this, specific genotypes of either -741, -1321, or their
combinations have been reported to be associated with the risk of lung [21, 27], head and neck
[20, 27], and liver [23] cancers. Similar associations with the survival outcomes of lung [24],
esophageal [25], hepatocellular [26] and pancreatic cancer [28] patients have also been
detected. However, these two indels were not evaluated for their potential associations with
the risk or survival outcomes in colorectal cancer before. In this study, we tested these associa-
tions in colorectal cancer cases and controls from Newfoundland.
Methods
Ethical approval
This study was approved by the Health Research Ethics Authority (HREA) of Newfoundland
and Labrador (Reference numbers 09.106 and 15.294). Since this was a secondary use of data,
no patient consent specific for this study was required.
Study cohorts
Cases and controls recruited to Newfoundland Familial Colorectal Cancer Registry (NFCCR)
were examined. NFCCR was described elsewhere in detail [29, 30]. In brief, participants (or
their family members) provided consent to participate in NFCCR. A total of 750 stage 0-IV
cases diagnosed between January 1999 and December 2003 were recruited. Age, sex and other
related demographic information was collected at the time of recruitment. Access to medical
records and blood or tissue samples were requested. Individuals free of colorectal cancer were
enrolled as controls in the year of 2004 and 2005 by random-digit-dialing [31]. Controls were
frequency-matched with the cases in terms of age and sex. In total, 720 controls were recruited.
Blood samples and demographic information using questionnaires were collected at the time
of recruitment. Cases who smoked cigarettes before the time of diagnosis were defined as ever-
smokers while those did not smoke till this time point were defined as never-smokers. For con-
trols, the time of recruitment was used as the time point to define ever-smoker and never-
smoker status. Body mass index (BMI) was calculated based on the body mass and height
information provided by the participants. For cases, these data were based on approximately
one year before the diagnosis and for controls, these data were based on approximately two
years before their recruitment.
Exclusion criteria for the study cohorts included: (1) cases and controls who were>75
years of age; (2) cases and controls who self-identified themselves as non-white or of mixed
race; those who did not provide this information were also excluded; (3) cases who were diag-
nosed with stage 0 disease; (4) cases who were affected by Lynch syndrome, familial colorectal
cancer type X (FCCX), or familial adenomatous polyposis (FAP); (5) cases who were the first,
second, or third degree relatives with each other; in such a case one of the patients were ran-
domly excluded. This information was based on a previously obtained genome-wide SNP
genotype data [11] and was available for all but three patients; (6) controls who had a known
first, second, or third degree relative in the case cohort; (7) controls who are known to have
BRM promoter indels and colorectal cancer risk and survival outcomes
PLOS ONE | https://doi.org/10.1371/journal.pone.0198873 June 12, 2018 3 / 17
developed colorectal cancer after recruitment; (8) controls with no epidemiological/demo-
graphic data; and (9) cases or controls without genomic DNA extracted from blood samples.
In the end, 427 cases and 408 controls passed these eligibility criteria. As for the survival analy-
sis, one patient with no prognosis-related data was excluded. Characteristics of the cases and
controls are summarized in Table 1.
Follow-up
Patients were followed until the year 2010. The median follow up was 6.98 years (range: 2.00–
10.88 years) with 95% confidence intervals (CIs) of 6.69–7.28 years (calculated based on
reverse Kaplan-Meier method [32] using IBM SPSS Statistics-23). Data on vital status and
occurrence of recurrence and metastasis were collected from various sources as explained in
Negandhi et al. [33]. In brief, collection of prognostic data was performed by NFCCR. Clinical
events of interest (i.e. recurrence/metastasis/death) were surveyed through and extracted/
obtained from the patients’ medical records, the Newfoundland Cancer Treatment and
Research Foundation database, or patient follow-up questionnaires.
DNA genotyping
All NFCCR cases and controls with available DNA samples were genotyped for the BRM pro-
moter indel polymorphisms (n = 493 for cases and n = 448 for controls). Genotyping for BRM
-741 and BRM -1321 promoter region polymorphisms was performed by two custom designed
Taqman assays (BRM-741: forward primer: 5’ TGGCAGGAACGTTCTTTGTG 3’; reverse
primer: 5’ TGCCGGCTGAAACTTTTTCT 3’; probe for insertion: /56-FAM/TCCCTTTT
CTA/ZEN/TTTTTTATTTTTTATTTTTTTACCTGGAA/3IABkFQ/; probe for wild-type:
/5HEX/CCTCCCTTTTC/ZEN/TATTTTTTATTTTTTTACCTGGAAT/3IABkFQ/;BRM-
1321: forward primer: 5’ CATACTTTTCATAACACTACTGCATAGGAACA 3’; reverse
primer: 5’ TTTTATGAAGTGTGAAAGAATGTTAGGAGACT 3’; probe for insertion: /56-
FAM/A+CT+CTTA+AAAT+T+AAAA+CTGT/3IABkFQ/;probe for wild-type: /5HEX/T+G+
CTT+GA+CT+CTTAA+AAC/3IABkFQ/. TaqMan assay reaction condition for BRM-741 and
-1321 polymorphisms was: 95˚C 2 min followed by 40 cycles of 95˚C for 6 sec / 60˚C for 20
sec. Reaction volume for each sample was 5μl. PCR master mix was obtained from Kapabiosys-
tems (Kapa probe fast qPCR kit, Cat#kk4702). For BRM-741 and BRM-1321, 9.58% and
19.26% of the DNA samples were genotyped twice and concordance rate was 100%. These
methods had been previously compared with Sanger sequencing, and two other sets of primers
and probes in 190 patients with 100% concordance.
A total of 831 (n = 424 of 427 cases, n = 407 of 408 controls) and 832 (n = 425 of 427 cases,
n = 407 of 408 controls) individuals included into the study were successfully genotyped for
the BRM-741 and BRM-1321 variants, respectively.
Statistical analysis
Hardy-Weinberg equilibrium (HWE) calculations were performed using an online calculator
(http://www.oege.org/software/hwe-mr-calc.shtml) [34]. D’ and r2 for linkage disequilibrium
(LD) between BRM-741 and BRM-1321 were calculated by using the LD function of genetics
package [35] in R (ver3.2.4) [36]. Chi-squared test was used to examine the differences
between cases and controls. All analyses were performed by using R (ver3.2.4) [36] unless oth-
erwise specified.
Similar to other studies, deletions (Del) were assigned as wild-type alleles, and insertions (Ins)
as variant alleles. Individual associations of the BRM-741 and BRM-1321 were analyzed under
different genetic models (co-dominant, dominant, recessive and additive genetic models).
BRM promoter indels and colorectal cancer risk and survival outcomes
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Combination analyses involving both polymorphisms were performed as follows: Category A)
the genotype categorizations used by the previous investigators [20, 21, 24, 25, 28]; Category B)
Table 1. Distribution of baseline characteristics of the study cohorts.
Characteristics Cases
N (%)
Controls
N (%)
 P value
Total 427 (100) 408 (100)
† Age 0.40
< 65 years 268 (62.76) 245 (60.05)
 65 years 158 (37.00) 163 (39.95)
Unknown 1 (0.23) -
Sex 0.91
Female 172 (40.28) 166 (40.69)
Male 255 (59.72) 242 (59.31)
Number of FDR with colorectal cancer 0.0004
0 304 (71.19) 333 (81.62)
At least 1 123 (28.81) 75 (18.38)
Smoking status 0.09
Never 124 (29.04) 143 (35.05)
Ever 296 (69.32) 265 (64.95)
Unknown 7 (1.64) -
‡ BMI 0.35
Underweight and normal 119 (27.87) 127 (31.13)
Overweight and obese 294 (68.85) 272 (66.67)
Unknown 14 (3.28) 9 (2.21)
§ Disease stage -
I 76 (17.84) -
II 167 (39.20) -
III 140 (32.86) -
IV 43 (10.09) -
§ Tumor location -
colon 280 (65.73) -
rectum 146 (34.27) -
§ MSI status -
MSS\MSI-L 368 (86.38) -
MSI-H 40 (9.39) -
Unknown 18 (4.23) -
§ Treatment with adjuvant chemotherapy -
No 189 (44.37) -
Yes 233 (54.69) -
Unknown 4 (0.94) -
BMI, body mass index; FDR, first-degree relative(s); MSI, microsatellite instability; MSI-H, microsatellite instability-
high; MSI-L, microsatellite instability-low; MSS, microsatellite stable; N, number. P values < 0.05 are bolded.
 Two-sided χ2 test for comparison between cases and controls with available data.
† Age is the age at diagnosis for cases, and age at recruitment for controls.
‡ Underweight, normal, overweight, and obese are defined as BMI <18.5, 18.5 BMI < 25, 25  BMI < 30,
BMI 30, respectively. Categorization criterion was based on the information provided on the website of National
Institutes of Health (https://www.nhlbi.nih.gov/health/educational/lose_wt/BMI/bmicalc.htm).
§ Total number of cases is 426.
https://doi.org/10.1371/journal.pone.0198873.t001
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double homozygous variant genotype (Ins/Ins+Ins/Ins) compared to others; Category C) double
wild-type genotype (Del/Del+Del/Del) compared to others; and Category D) at least one homo-
zygous variant genotype compared to others (shown in S1 Table; Categories A-D).
Association analyses. In the case-control study, unconditional logistic regression analyses
were applied to test the associations between the indels and the risk of colorectal cancer.
Known risk factors (age, sex, and number of first-degree relatives (FDR) with colorectal can-
cer) were included in multivariable models. Smoking status and BMI were sequentially exam-
ined using the log likelihood ratio test. We first examined smoking status and compared
models with and without this variable. As the models were significantly different from each
other (P values < 0.001) and the model with this variable had a smaller Akaike Information
Criterion (AIC) value [37] (and, thus improved model’s fit to data), smoking status was
included as a covariate in the baseline model. We then examined BMI and obtained similar
results. Thus, BMI was also included in the final baseline model as a covariate. Odds ratios
(ORs) and 95% CIs for the genotypes were calculated under the multivariate logistic regression
models adjusted for the baseline variables.
Cox Proportional Hazards (PH) regression method was used for survival analyses. The out-
come of interest was progression-free survival that was defined as the time from diagnosis till
the time of death, or, local or distant recurrence. Patients were censored if they experienced
none of the events (death, recurrence or metastasis) till the last follow-up. The proportional
hazard assumption was tested by using the cox.zph function [38] in R (ver3.2.4) [36]. Age was
the only variable that violated the PH assumption (including genotypes), thus multivariate
models were stratified by age. Other model covariates included disease stage, tumor location,
microsatellite instability (MSI) status, and treatment status (adjuvant chemotherapy Yes/No).
Their independent associations with the outcome were confirmed in a multivariable baseline
model. Hazard ratios (HRs) and corresponding 95% CIs for the genotype categories were esti-
mated under the age-stratified multivariate Cox models adjusting for these baseline variables.
Sub-cohort analyses. To explore whether the associations of these indels vary by sex and
tumor location (colon, rectum), we also performed sub-cohort analyses separately (S2–S5
Tables). Adjustments in sub-cohort analyses were done by the covariates previously selected,
except for the covariate sex in the risk analyses in male and female sub-cohorts, and tumor
location in survival analyses in colon and rectal cancer sub-cohorts. In addition, MSI was not
included as a covariate in survival analyses of rectal cancer cases because there were only two
rectal cancer patients with microsatellite instability-high (MSI-H) tumors.
Results
Minor allele frequencies, Hardy-Weinberg equilibrium test, and linkage
disequilibrium between the BRM-741 and BRM-1321 indels
Minor allele frequencies of BRM-741 and BRM-1321 were 48% and 44% in controls and 47%
and 43% in cases, respectively. Both BRM-741 and BRM-1321 genotype frequencies satisfied
the HWE in controls. D’ and the r2 between the BRM-741 and BRM-1321 were lower than 0.8
in cases (D’ = 0.48; r2 = 0.20) and controls (D’ = 0.58; r2 = 0.29), indicating the two polymor-
phisms were not highly correlated with each other in this population.
Associations of the BRM-741 and BRM-1321 indels with the susceptibility
to colorectal cancer
Case-control analyses in colorectal cases and controls. Cases (n = 427) and controls
(n = 408) were comparable to each other in terms of frequency distribution of age, sex,
BRM promoter indels and colorectal cancer risk and survival outcomes
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smoking status, and BMI, except the number of FDR affected by colorectal cancer as expected
(Table 1). After adjusting for age, sex, number of FDR, smoking status, and BMI, BRM indels
were not associated with the risk of colorectal cancer when analyzed alone or together
(Table 2).
Case-control analyses in the sub-cohorts. In multivariate analyses, significant associa-
tions were found only in the colon cases and when the BRM-741 and BRM-1321 indel geno-
types were analyzed together (Table 3). Specifically, compared to double wild-type genotype
(Del/Del+Del/Del), no homozygous or one homozygous variant genotypes were associated
with the increased risk of colon cancer (no homozygous variant genotype; OR [95% CI] = 1.65
[1.05–2.63]; P value = 0.03; one homozygous variant genotype; OR [95% CI] = 1.77 [1.05–
3.01]; P value = 0.03; Category A). Additionally, compared to the double wild-type genotype
(Del/Del+Del/Del), combined genotypes that included at least one variant allele were associ-
ated with increased risk of colon cancer (OR [95% CI] = 1.60 [1.04–2.50]; P value = 0.03; Cate-
gory C). There were no associations detected in the rectal cancer, female, or male cancer sub-
cohorts (S2 and S3 Tables).
Only the results with P value less than 0.05 are shown in this table; all results obtained in
the sub-cohort analyses are shown in S2 and S3 Tables.
Associations of the BRM-741 and BRM-1321 indels with progression-free
survival in colorectal cancer
Survival analyses in the colorectal cancer cases. Results are summarized in Table 4. The
only association was detected under the co-dominant genetic model where the heterozygosity
for the BRM-741 indel was significantly associated with longer progression-free survival time
when compared to wild-type genotype (Ins/Del vs Del/Del; HR [95% CI] = 0.67 [0.45, 0.98]; P
value = 0.04; Fig 1). This association was independent of age, disease stage, tumor location,
MSI and adjuvant chemotherapy status.
Survival analyses in the sub-cohorts. In the male colorectal cancer cohort, BRM-741
indel was associated with the progression-free survival time under the co-dominant and reces-
sive genetic models (S4 Table). Similar to the results obtained in the entire patient cohort
(Table 4), under the co-dominant genetic model heterozygosity for BRM-741 was associated
with longer progression-free survival time compared to wild-type genotype (HR [95% CI] =
0.54 [0.34, 0.88]; P value = 0.01). This pattern was also evident in the Kaplan-Meier curves
where the male patients with the wild-type Del/Del and the homozygous Ins/Ins genotypes
had similar survival probabilities compared to heterozygous Ins/Del individuals who had bet-
ter survival probability (S1 Fig). A stronger association was detected under the recessive
genetic model, where the homozygosity for the BRM-741 Ins allele was associated with
decreased progression-free survival time compared to other genotypes (HR [95% CI] = 1.84
[1.17, 2.90]; P value = 0.009; S2 Fig). These associations were restricted to the male patients
and were not detected in female, colon, or rectal cancer cases (S4 and S5 Tables).
Discussion
In this study, for the first time we have investigated whether two functional variants (BRM-741
and BRM-1321) located in the promoter region of the BRM gene were associated with the sus-
ceptibility to develop colorectal cancer and survival times of the patients. Our results show that
presence of at least one variant allele in both of these indels are associated with the increased
risk of colon but not rectal cancer. Our results also show that BRM-741 may be associated with
progression-free survival time in colorectal cancer patients, particularly in the male patients.
BRM promoter indels and colorectal cancer risk and survival outcomes
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Table 2. BRM promoter indels and colorectal cancer risk.
Variable Genotypes Cases
N (%)
Controls
N (%)
OR (95% CI)  P value
BRM-741
Co-dominant model
Del/Del (wild-type) 119 (27.87) 113 (27.70) 1 (reference)
Ins/Del 215 (50.35) 201 (49.26) 1.09 (0.78, 1.52) 0.61
Ins/Ins 90 (21.08) 93 (22.79) 0.96 (0.64, 1.44) 0.85
Unknown 3 (0.70) 1 (0.25)
Dominant model
Del/Del 119 (27.87) 113 (27.70) 1 (reference)
Ins/Ins + Ins/Del 305 (71.43) 294 (72.06) 1.05 (0.77, 1.44) 0.76
Unknown 3 (0.70) 1 (0.25)
Recessive model
Ins/Del + Del/Del 334 (78.22) 314 (76.96) 1 (reference)
Ins/Ins 90 (21.08) 93 (22.79) 0.91 (0.65, 1.28) 0.59
Unknown 3 (0.70) 1 (0.25)
† Additive model
Del/Del 119 (27.87) 113 (27.70) 0.99 (0.81, 1.21) 0.90
Ins/Del 215 (50.35) 201 (49.26)
Ins/Ins 90 (21.08) 93 (22.79)
Unknown 3 (0.70) 1 (0.25)
BRM-1321
Co-dominant model
Del/Del (wild-type) 136 (31.85) 135 (33.09) 1 (reference)
Ins/Del 213 (49.88) 188 (46.08) 1.20 (0.87, 1.65) 0.27
Ins/Ins 76 (17.80) 84 (20.59) 0.93 (0.62, 1.39) 0.73
Unknown 2 (0.47) 1 (0.25)
Dominant model
Del/Del 136 (31.85) 135 (33.09) 1 (reference)
Ins/Ins + Ins/Del 289 (67.68) 272 (66.67) 1.11 (0.83, 1.51) 0.48
Unknown 2 (0.47) 1 (0.25)
Recessive model
Ins/Del + Del/Del 349 (81.73) 323 (79.17) 1 (reference)
Ins/Ins 76 (17.80) 84 (20.59) 0.84 (0.58, 1.19) 0.32
Unknown 2 (0.47) 1 (0.25)
† Additive model
Del/Del 136 (31.85) 135 (33.09) 0.99 (0.81, 1.21) 0.93
Ins/Del 213 (49.88) 188 (46.08)
Ins/Ins 76 (17.80) 84 (20.59)
Unknown 2 (0.47) 1 (0.25)
‡ BRM-741 and BRM-1321
genotype combinations
Category A.
Double wild-type genotype 73 (17.10) 81 (19.85) 1 (reference)
No homozygous variant genotype 223 (52.22) 196 (48.04) 1.36 (0.92, 2.00) 0.12
One homozygous variant genotype 91 (21.31) 81 (19.85) 1.32 (0.84, 2.08) 0.23
Double homozygous variant genotype 37 (8.67) 48 (11.76) 0.90 (0.51, 1.56) 0.70
Unknown 3 (0.70) 2 (0.49)
Category B.
(Continued)
BRM promoter indels and colorectal cancer risk and survival outcomes
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BRM codes for one of the two ATPase subunits of the SWI/SNF complex [12]. Two indel
polymorphisms in the promoter region of BRM, BRM-741 and BRM-1321, have been shown
to be associated with down-regulation of this gene [21], and therefore may affect the function
of the SWI/SNF complex and cellular processes regulated by it. Some of these cellular
Table 2. (Continued)
Variable Genotypes Cases
N (%)
Controls
N (%)
OR (95% CI)  P value
Other genotype combinations 387 (90.63) 358 (87.75) 1 (reference)
Double homozygous variant genotype 37 (8.67) 48 (11.76) 0.71 (0.44, 1.13) 0.15
Unknown 3 (0.70) 2 (0.49)
Category C.
Double wild-type genotype 73 (17.10) 81 (19.85) 1 (reference)
Other genotype combinations 351 (82.20) 325 (79.66) 1.28 (0.89, 1.84) 0.19
Unknown 3 (0.70) 2 (0.49)
Category D.
Other genotype combinations 296 (69.32) 277 (67.89) 1 (reference)
At least one homozygous variant genotype 128 (29.98) 129 (31.62) 0.93 (0.68, 1.26) 0.63
Unknown 3 (0.70) 2 (0.49)
CI, confidence interval; Del, deletion; Ins, insertion; N, number; OR, odds ratio.
 Adjusted for age, sex, number of first degree relatives with colorectal cancer, smoking status, and body mass index. Please note that final models include only the
patients with the available covariate data. For further information on genotype combinations/categories, please refer to Methods/S1 Table.
† Ins/Ins vs Ins/Del vs Del/Del.
‡ Homozygous variant genotype is Ins/Ins genotype.
https://doi.org/10.1371/journal.pone.0198873.t002
Table 3. Associations between BRM promoter indels and colon cancer risk.
Sub-cohort Variable Genotypes Cases
N (%)
Controls
N (%)
OR (95% CI)  P value
Colon cases
+ Controls
† BRM-741 and BRM-1321 genotype
combination
Category A.
Double wild-type genotype 41 (14.64) 81 (19.85) 1 (reference)
No homozygous variant genotype 148
(52.86)
196
(48.04)
1.65 (1.05,
2.63)
0.03
One homozygous variant genotype 64 (22.86) 81 (19.85) 1.77 (1.05,
3.01)
0.03
Double homozygous variant
genotype
25 (8.93) 48 (11.76) 1.14 (0.60,
2.15)
0.69
Unknown 2 (0.71) 2 (0.49)
Category C.
Double wild-type genotype 41 (14.64) 81 (19.85) 1 (reference)
Other genotype combinations 237
(84.64)
325
(79.66)
1.60 (1.04,
2.50)
0.03
Unknown 2 (0.71) 2 (0.49)
CI, confidence interval; N, number; OR, odds ratio. P values < 0.05 are bolded.
 Adjusted for age, sex, number of first degree relatives with colorectal cancer, smoking status and body mass index. Please note that final models include only the
patients with the available covariate data. For further information on genotype combinations/categories, please refer to Methods/S1 Table.
† Homozygous variant genotype is Ins/Ins genotype.
https://doi.org/10.1371/journal.pone.0198873.t003
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Table 4. BRM promoter indels and progression-free survival in colorectal cancer.
Variable Genotypes Cases
N (%)
P value for PH assumption test HR (95% CI)  P value
BRM-741
Co-dominant model
Del/Del (wild-type) 119 (27.93) 1 (reference)
Ins/Del 215 (50.47) 0.72 0.67 (0.45, 0.98) 0.04
Ins/Ins 89 (20.89) 0.95 0.97 (0.62, 1.51) 0.89
Unknown 3 (0.70)
Dominant model
Del/Del 119 (27.93) 1 (reference)
Ins/Ins + Ins/Del 304 (71.36) 0.86 0.75 (0.53, 1.07) 0.12
Unknown 3 (0.70)
Recessive model
Ins/Del + Del/Del 334 (78.40) 1 (reference)
Ins/Ins 89 (20.89) 0.81 1.24 (0.85, 1.82) 0.27
Unknown 3 (0.70)
† Additive model
Del/Del 119 (27.93)
Ins/Del 215 (50.47) 0.96 0.96 (0.75, 1.21) 0.72
Ins/Ins 89 (20.89)
Unknown 3 (0.70)
BRM-1321
Co-dominant model
Del/Del (wild-type) 136 (31.92) 1 (reference)
Ins/Del 212 (49.77) 0.45 0.95 (0.66, 1.36) 0.76
Ins/Ins 76 (17.84) 0.64 0.98 (0.61, 1.58) 0.93
Unknown 2 (0.47)
Dominant model
Del/Del 136 (31.92) 1 (reference)
Ins/Ins + Ins/Del 288 (67.61) 0.44 0.95 (0.68, 1.34) 0.79
Unknown 2 (0.47)
Recessive model
Ins/Del + Del/Del 348 (81.69) 1 (reference)
Ins/Ins 76 (17.84) 0.88 1.01 (0.66, 1.55) 0.96
Unknown 2 (0.47)
† Additive model
Del/Del 136 (31.92)
Ins/Del 212 (49.77) 0.54 0.98 (0.78, 1.24) 0.88
Ins/Ins 76 (17.84)
Unknown 2 (0.47)
‡ BRM-741 and BRM-1321
genotype combinations
Category A.
Double wild-type genotype 73 (17.14) 1 (reference)
No homozygous variant genotype 223 (52.35) 0.56 0.66 (0.43, 1.00) 0.05
One homozygous variant genotype 90 (21.13) 0.60 0.72 (0.44, 1.18) 0.19
Double homozygous variant genotype 37 (8.69) 0.58 1.02 (0.55, 1.89) 0.96
Unknown 3 (0.70)
Category B.
(Continued)
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Table 4. (Continued)
Variable Genotypes Cases
N (%)
P value for PH assumption test HR (95% CI)  P value
Other genotype combinations 386 (90.61) 1 (reference)
Double homozygous variant genotype 37 (8.69) 0.60 1.39 (0.81, 2.38) 0.24
Unknown 3 (0.70)
Category C.
Double wild-type genotype 73 (17.14) 1 (reference)
Other genotype combinations 350 (82.16) 0.79 0.71 (0.48, 1.05) 0.09
Unknown 3 (0.70)
Category D.
Other genotype combinations 296 (69.48) 1 (reference)
At least one homozygous variant genotype 127 (29.81) 0.51 1.07 (0.76, 1.52) 0.69
Unknown 3 (0.70)
CI, confidence interval; Del, deletion; HR, hazard ratio; Ins, insertion; N, number; PH, proportional hazard. P values < 0.05 are bolded. For further information on
genotype combinations/categories, please refer to Methods/S1 Table.
 Results by age stratified Cox models adjusted for disease stage, tumor location, microsatellite instability (MSI) status, and treatment status (adjuvant chemotherapy Yes
or No).
† Ins/Ins vs Ins/Del vs Del/Del.
‡ Homozygous variant genotype is Ins/Ins genotype.
https://doi.org/10.1371/journal.pone.0198873.t004
Fig 1. Kaplan-Meier curves for the BRM-741 indel under the co-dominant genetic model in the colorectal cancer
cases. P value of the log-rank test is 0.017.
https://doi.org/10.1371/journal.pone.0198873.g001
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processes are related to cancer, such as cell proliferation and differentiation [39], making these
two genetic variants functionally interesting in cancer research. These variants are not
included in many of the genotyping platforms and are not in high LD with other platform
polymorphisms to be accurately imputed [21]. This means that the potential associations of
these two BRM variants may have been missed in genome-wide studies, including one of ours
in the NFCCR patient cohort [11]. A number of research groups genotyped and studied the
associations of BRM-741 and BRM-1321 indels with the risk or survival outcomes in various
solid cancers. As it is summarized below, while the particular genotypes that are associated
with the risk of disease or clinical outcomes are not consistent across different cancer sites, it
has been so far consistent that when an association is detected, the variant allele containing
genotypes were associated with increased risk of disease/clinical events compared to the homo-
zygous wild-type genotypes. These findings suggest that down-regulation of BRM may have a
role in carcinogenesis or progression in these cancers.
Studies published so far have showed that either or both of the BRM-741 and BRM-1321
indels are associated with the risk of development of cancer in multiple, but not all, tissues
examined. For example, in stage I-II lung and head and neck cancer patients, one study identi-
fied the association of the double homozygous variant genotype with increased disease risk
[27]. Two other studies involving stage I-IV patients reported similar associations, in addition
to associations of -741 (Ins/Ins genotype) and -1321 (Ins allele containing genotypes), with
increased risks of lung cancer [21] as well as head and neck cancers [20]. Additionally, in two
separate patient cohorts from Asia, BRM-741 was not found to be associated with the disease
risk, whereas both the heterozygosity and homozygosity for the BRM-1321 Ins allele were asso-
ciated with increased risk of liver cancer [23]. However, these associations were not detected
in a Canadian cohort in a recent study [26]. Additionally, no associations were found between
the two indels and the disease risk in pancreatic cancer (when analyzed either alone or in com-
bination) [28], or in early stage esophageal cancer patients (when analyzed in combination)
[27].
In colorectal cancer patients, including the male and female sub-cohorts, our multivariate
analyses detected no associations of the BRM-741 and BRM-1321 indels with the disease risk
when these variants were analyzed individually or in combination. However, when the analysis
was restricted to the colon cancer patients, genotypes containing at least one variant allele
were associated with increased risk of colon cancer compared to the double wild-type genotype
(Del/Del+Del/Del) (Table 3 –Category C). These associations were independent of age, sex,
number of first degree relatives with colorectal cancer, smoking status, and body-mass index.
Additionally, as also shown in Table 3 (Category A), no homozygous and one homozygous
genotypes were associated with increased risk of colon cancer compared to double wild type
genotype. While we have not observed the association of the double homozygous variant geno-
type with increased cancer risk compared to double homozygous wild type genotype (likely
because of the rarity of this genotype in our cases and controls; Table 3 –Category A), the fact
that the presence of the variant alleles associates with increased colon cancer risk is biologically
in line with the findings in other cancers. Therefore, similar to other cancer sites (e.g. lung and
head and neck cancers [20, 21, 27]) our results suggest that the loss or reduced expression of
BRM may increase the colon cancer risk. Interestingly, another gene coding for a subunit of
the SWI/SNF complex (ARID1A/BAF250A) has been found to have frameshift or nonsense
mutations in up to 10% of colon tumors [40], suggesting that abnormalities in ARID1A pro-
tein may have a role colon carcinogenesis. Together with our results, these findings suggest the
possible involvement of the SWI/SNF complex in colon carcinogenesis. Overall, once con-
firmed in other patient cohorts our results may have significant implications for understand-
ing the biological functions of the BRM gene and the SWI/SNF complex, and their potential
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roles in pathogenesis or treatment of colon cancer. In contrast, there was no evidence of asso-
ciations of the BRM indels with the risk of rectal cancer. This may be attributed to insufficient
power in the rectal cancer cohort (n = 146), or the fact that colon and rectal cancers are sepa-
rate cancer sites arising in distinct tissues characterized with different pathogenesis and molec-
ular alterations [41]. Further cohort and/or molecular studies can be valuable in addressing
this hypothesis.
Similar to susceptibility studies, associations of the BRM-741 and BRM-1321 indels with
survival outcomes have been reported in multiple cancer sites. For example, in pancreatic as
well as in esophageal cancers, one or two copies of the indel variant alleles (Ins/Del, Ins/Ins) or
double homozygous variant genotype (Ins/Ins+Ins/Ins) were associated with reduced overall
survival time [25, 28]. Additionally, in two separate stage III-IV non-small cell lung cancer
cohorts, homozygosity for the variant alleles of either indels as well as the double homozygous
variant genotype were associated with shortened overall and progression-free survival time
[24]. A recent study on liver cancer patients also showed similar associations between overall
survival time and these indel variants [26]. In our study, no associations were detected between
the progression-free survival time of the patients and the BRM-1321 genotypes or the genotype
combinations of the BRM-741 and BRM-1321 indels. However, associations were detected for
the BRM-741 genotypes. Specifically, when compared to the wild-type genotype (Del/Del),
heterozygosity for the BRM-741 indel was associated with longer progression-free survival
time in the colorectal cancer cohort independent of age, disease stage, tumor location, MSI
and adjuvant treatment status (Table 4; Fig 1). A similar association was also detected in the
male colorectal cancer patients (S4 Table; S1 Fig). Based on the previous studies on other can-
cers, we would expect the wild-type genotype to have better survival outcomes compared to
the genotypes that include the variant allele. However, our results do not support this assump-
tion. We also note that it is possible that the small sample size in the wild-type homozygous
genotype group may have led to missing a possible association. In addition, under the recessive
genetic model we found that the male patients who had the Ins/Ins genotype of BRM-741 had
shorter survival times compared to the rest of the male patients (S4 Table; S2 Fig). This associa-
tion was not detected in the female patients (p> 0.05: S4 Table). However, as shown in S3 Fig,
while it did not reach significance, an opposite effect of the Ins/Ins allele in the female patients
was observable, suggesting that the prognostic associations of the BRM-741 may be different
between male and female colorectal cancer patients. This opens new research avenues for
future studies that can help dissect the biological basis of sex-based differences in colorectal
cancer outcomes.
Strengths/limitations of this study can be summarized as follows: replications in indepen-
dent patient cohorts are required to rule out false-positive associations and to confirm our
results; death from any cause was used as one of the endpoints as the cause of death informa-
tion was not available for all patients; and the low frequency of the double homozygous variant
genotype has possibly prevented examination/detection of its potential associations in our
cohort, thus analysis of larger patient cohorts are needed. However, to our knowledge, this is
the first study that investigated the association between the BRM-741 and BRM-1321 promoter
variations and disease risk and patient survival outcomes in colorectal cancer; the patient
cohort is a well described cohort with long follow-up time (median: 6.98 years); a comprehen-
sive investigation has been conducted including application of multiple genetic models and
sub-group analyses; and more importantly, in the survival analysis the proportional hazard
assumption of the Cox regression method has been assessed and appropriate models have
been constructed, which makes our estimations more reliable [42, 43].
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Conclusions
In conclusion, our results suggest the potential involvement of BRM in colon cancer pathogen-
esis and colorectal cancer progression. Analyses in larger and additional patient cohorts are
needed to verify our results.
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